(2022). Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists. Int J Chron Obstruct Pulmon Dis, 17, 1715-1733. http://doi.org/10.2147/copd.s363997.
(2022). Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany. Clin Drug Investig. http://doi.org/10.1007/s40261-022-01120-2.
(2018). GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD). Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.4448.
(2019). Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom. Respir Med. http://doi.org/10.1016/j.rmed.2019.04.018.
(2021). A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink. Int J Chron Obstruct Pulmon Dis. http://doi.org/10.2147/copd.s301624.